surmount trial tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 SURMOUNT-1: Tirzepatide Drastically Reduces Weight – ESC 2025: post-hoc SURMOUNT-5 data
Pay in 4 interest-free payments of $5.97 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5


























